Residual Coronary Risk Factors Associated With Long-Term Clinical Outcomes in Patients With Coronary Artery Disease Treated With High- vs. Low-Dose Statin Therapy ― REAL-CAD Substudy ―
Circulation Journal · 2024
DOI: 10.1253/circj.cj-23-0134 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation Journal, 2024. Verfasst von Takumi Higuma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Kawasaki Municipal Tama Hospital. Hauptthemen laut MEDLINE: Coronary Artery Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Glomerular Filtration Rate. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: It remains unclear which comorbidities, other than lipid parameters, or combination of comorbidities, best predicts cardiovascular events in patients with known coronary artery disease (CAD) treated with statins. Therefore, we aimed to identify the nonlipid-related prognostic factors and risk stratification of patients with stable CAD enrolled in the REAL-CAD study. METHODS AND RESULTS: Blood pressure, glucose level, and renal function were considered as risk factors in the 11,141 enrolled patients. The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and unstable angina. The secondary composite endpoint was the primary endpoint and/or coronary revascularization. A significantly worse prognosis at the primary endpoint was observed in the estimated glomerular filtration rate (eGFR) ≤60 group, and the combination of eGFR ≤60 and HbA1c ≥6.0 was the worst (hazard ratio (HR) 1.66; P 60 group, systolic blood pressure (SBP) ≥140 mmHg met the secondary endpoint (HR 1.33; P=0.006), and the combination of eGFR ≤60 and HbA1c ≥6.0 was also the worst at the secondary endpoint (HR 1.35; P=0.002). CONCLUSIONS: Regarding nonlipid prognostic factors contributing to the incidence of cardiovascular events in statin-treated CAD patients, renal dysfunction was the most significant, followed by poor glucose control and high SBP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Kawasaki Municipal Tama Hospital.
- Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine.
- Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine.
- Biostatistics Center, Kurume University.
- Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.
- Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine.
Zitieren
APA
Higuma, T., Akashi, Y. J., Fukumoto, Y., Obara, H., Kakuma, T., Asaumi, Y., Yasuda, S., Sakuma, I., Daida, H., Shimokawa, H., Kimura, T., Iimuro, S., & Nagai, R. (2024). Residual Coronary Risk Factors Associated With Long-Term Clinical Outcomes in Patients With Coronary Artery Disease Treated With High- vs. Low-Dose Statin Therapy ― REAL-CAD Substudy ―. Circulation Journal. https://doi.org/10.1253/circj.cj-23-0134
Vancouver
Higuma T, Akashi YJ, Fukumoto Y, Obara H, Kakuma T, Asaumi Y, et al. Residual Coronary Risk Factors Associated With Long-Term Clinical Outcomes in Patients With Coronary Artery Disease Treated With High- vs. Low-Dose Statin Therapy ― REAL-CAD Substudy ―. Circulation Journal. 2024. doi:10.1253/circj.cj-23-0134
BibTeX
@article{Higuma2024,
author = {Higuma, Takumi and Akashi, Yoshihiro J and Fukumoto, Yoshihiro and Obara, Hitoshi and Kakuma, Tatsuyuki and Asaumi, Yasuhide and Yasuda, Satoshi and Sakuma, Ichiro and Daida, Hiroyuki and Shimokawa, Hiroaki and Kimura, Takeshi and Iimuro, Satoshi and Nagai, Ryozo},
title = {Residual Coronary Risk Factors Associated With Long-Term Clinical Outcomes in Patients With Coronary Artery Disease Treated With High- vs. Low-Dose Statin Therapy ― REAL-CAD Substudy ―},
journal = {Circulation Journal},
year = {2024},
doi = {10.1253/circj.cj-23-0134}
}
EUVIMED